Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,808 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists.
Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A, Hardcastle AJ, Kooij G, de Vries HE, Amor S, Thomas SA, Ledent C, Marsicano G, Lutz B, Thompson AJ, Selwood DL, Giovannoni G, Baker D. Pryce G, et al. Among authors: baker d. FASEB J. 2014 Jan;28(1):117-30. doi: 10.1096/fj.13-239442. Epub 2013 Oct 11. FASEB J. 2014. PMID: 24121462
Multiple sclerosis: variations on a theme.
Amor S, Baker D, Layward L, McCormack K, van Noort JM. Amor S, et al. Among authors: baker d. Immunol Today. 1997 Aug;18(8):368-71. doi: 10.1016/s0167-5699(97)01100-6. Immunol Today. 1997. PMID: 9267077 No abstract available.
Endocannabinoids control spasticity in a multiple sclerosis model.
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V. Baker D, et al. FASEB J. 2001 Feb;15(2):300-2. doi: 10.1096/fj.00-0399fje. Epub 2000 Dec 8. FASEB J. 2001. PMID: 11156943
Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.
Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJ, Brown P, Bridges D, Ledent C, Bifulco M, Rice AS, Di Marzo V, Baker D. Brooks JW, et al. Among authors: baker d. Eur J Pharmacol. 2002 Mar 29;439(1-3):83-92. doi: 10.1016/s0014-2999(02)01369-9. Eur J Pharmacol. 2002. PMID: 11937096
5,808 results